Skip to main content

Table 1 Patient and pathology characteristics

From: Minimal residual disease detection by multicolor flow cytometry in cryopreserved ovarian tissue from leukemia patients

Patient no Age at OTC Type of leukemia Treatment received before OTC LAIP identified at diagnosis Molecular marker at diagnosis
IV, IM or per os IT CED DIE
1 29 B-ALL 1, 2, 11, 15, 18 1, 11, 14 0 0 CD10 (100%), CD19 (100%), CD20 (87%0, CD22 (100%), CD34 (78%), CD38 (100%), CD58 (100%), CD200 (62%), CD304 (78%), cMPO (81%), oCD22 (99%), cTDT (73%), cCD79a (99%) BCR-ABL1
2 31 B-ALL 1, 2, 3, 4, 5, 6, 11, 12 1, 11, 14 2 500 175 CD19 (100%), CD22 (96%), cyCD22 (94), CD34 (100%), CD38 (99%), CD44 (98%), CD58 (98%), CD123 (99%), cyTDT (90%), cyCD79a (94%) Ig/TCR
3 14 B-ALL 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 14, 15 1, 11, 14 1 464 191 CD19 (91%), CD34 (87%), negative for CD10 and myeloid markers Ig/TCR
4 12 B-ALL 1, 2, 3, 5, 6, 11 1, 11, 19 0 24 CD45 (88%), HLA DRII (88%), CD10 (78%), CD19 (78%), CD22 (82%), CD33 (35%) Ig/TCR
5 5 B-ALL 1, 2, 3, 4, 5, 6, 7, 9, 19, 11, 12, 13, 14, 15 1, 11, 14, 19 2 500 314 CD19 (86%), CD10 (98%), CD22 (90%) CD38 (99%) Unkown
6 5 B-ALL 1, 2, 3, 6, 7, 8, 9, 10, 11, 12, 14, 15 1, 11, 19 610 87 CD45 (12%), CD10 (87%), CD19 (79%), CD22 (86%), CD34 (70%) HLA-DRII (81%) Ig/TCR
7 14 T-ALL 1, 2, 3, 4, 6, 11, 12, 15, 20 1, 11, 14 2 000 100 CD2 (89%), cyCD3 (94%), CD5 (93%), CD7 (98%), CD10 (49%), CD33 (81%), CD34 (89%), CD45RA (99%), CD123 (56%) None
8 22 T-ALL 1, 2, 3, 4, 6, 16 1, 11, 14 1 000 133 CD2 (76%), CD7 (94%), CD13 (98%), CD10 (80%), cyCD3 (83%), cyCD79 (80%) None
9 33 AML 1, 3, 17 1, 11, 14 0 300 CD13 (100%), cyCD13 (100%), CD15 (55%), CD33 (100%), CD34 (100%), CD38 (100%), CD117 (100%), cMPO (100%) CBFB-MYH11
10 15 AML 1 1, 11, 19 0 373 CD34 (96%), CD33 (98%), CD13 (54,5%), CD117 (47%), CD38 (40,5%) WT1
11 22 AML 1, 3, 17 1, 11,14 0 300 CD7 (80%), CD11b (83%), CD13 (96%), cCD13 (66%), CD19 (51%), CD33 (96%), CD34 (100%), CD38 (100%), CD71 (93%), CD117 (100%), cyMPO (100%), HLA DR (92%) WT1
12 15 AML 1, 13 1, 11, 19 0 240 CD13 (90%), CD33 (99%), CD117 (99%), CD65 (86%), CD7 (99%), HLA DR2 (97%), CD34 (98%), CD38 (98%) CEBPA mutations
13 14 AML 1, 13, 16 1, 11, 19 0 48 CD13 (100%), CD33 (100%), CD65 (100%), CD117 (100%), et CD11c (100%) Unknown
14 26 AML None None 0 0 CD13 (100%), CD33 (100%), CD117 (100%), CD34 (100%), CD38 (100%), CD123 (89%), cyMPO (100%), cyCD13 (100%) None
15 27 AML 1, 4, 14, 15, 16, 17, 21 None 0 225 CD34 (100%), CD33 (50%), CD38 (100%), HLA DR (100%), CD99 (50) BCR-ABL1
  1. OTC ovarian tissue cryopreservation, MRD minimal residual disease, LAIP leukemia-associated immunophenotype, IV intravenous, IM intramuscular, IT intrathecal, CED cyclophosphamide equivalent dose, DIE doxorubicin isotoxic equivalent, B-ALL B-cell acute lymphoblastic leukemia, T-ALL T-cell acute lymphoblastic leukemia, AML acute myeloid leukemia, Ig immunoglobulin rearrangement genes, TCR T-cell receptor rearrangement genes
  2. 1 indicates cytarabine, 2 vincristine, 3 daunorubicin, 4 cyclophosphamide, 5 etoposide, 6 asparaginase, 7 doxorubicin, 8 ifosfamide, 9 thioguanine, 10 vindesine, 11 methotrexate, 12 mercaptopurine, 13 mitoxantrone, 14 prednisolone, 15 dexamethasone, 16 amsacrine, 17 idarubicin, 18 imatinib, 19 hydrocortisone, 20 vinblastine, 21 gemtuzumab
  3. See Additional file 1 for CED and DIE calculation
Back to article page

Journal of Ovarian Research

ISSN: 1757-2215

Contact us